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Abstract
Objective
To synthesise lessons learnt and determinants of success from human papillomavirus
(HPV) vaccine demonstration projects and national programmes in low- and middle-income
countries (LAMICs).
Methods
Interviews were conducted with 56 key informants. A systematic literature review identified
2936 abstracts from five databases; after screening 61 full texts were included. Unpublished
literature, including evaluation reports, was solicited from country representatives; 188 doc-
uments were received. A data extraction tool and interview topic guide outlining key areas of
inquiry were informed by World Health Organization guidelines for new vaccine introduction.
Results were synthesised thematically.
Results
Data were analysed from 12 national programmes and 66 demonstration projects in 46
countries. Among demonstration projects, 30 were supported by the GARDASIL® Access
Program, 20 by Gavi, four by PATH and 12 by other means. School-based vaccine delivery
supplemented with health facility-based delivery for out-of-school girls attained high cover-
age. There were limited data on facility-only strategies and little evaluation of strategies to
reach out-of-school girls. Early engagement of teachers as partners in social mobilisation,
consent, vaccination day coordination, follow-up of non-completers and adverse events was
considered invaluable. Micro-planning using school/ facility registers most effectively enu-
merated target populations; other estimates proved inaccurate, leading to vaccine under- or
PLOS ONE | https://doi.org/10.1371/journal.pone.0177773 June 2, 2017 1 / 18
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Gallagher KE, Howard N, Kabakama S,
Mounier-Jack S, Griffiths UK, Feletto M, et al.
(2017) Lessons learnt from human papillomavirus
(HPV) vaccination in 45 low- and middle-income
countries. PLoS ONE 12(6): e0177773. https://doi.
org/10.1371/journal.pone.0177773
Editor: Jagat Kumar Roy, Banaras Hindu
University, INDIA
Received: August 12, 2016
Accepted: May 2, 2017
Published: June 2, 2017
Copyright: © 2017 Gallagher et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All anonymised data
are available publicly in the LSHTM Research
Online repository; URL: http://researchonline.
lshtm.ac.uk/3351522/.
Funding: This work was supported by the Bill &
Melinda Gates Foundation [grant OPP1115326].
The findings and conclusions contained within are
those of the authors and do not necessarily reflect
positions or policies of the Bill & Melinda Gates
Foundation or PATH. The funders had no role in
over-estimation. Refresher training on adverse events and safe injection procedures was
usually necessary.
Conclusion
Considerable experience in HPV vaccine delivery in LAMICs is available. Lessons are gen-
erally consistent across countries and dissemination of these could improve HPV vaccine
introduction.
Introduction
Globally, an estimated 528,000 new cervical cancer cases and 266,000 deaths occur annually
[1]. Over 85% of new cervical cancer cases occur in women living in low and middle-income
countries (LAMICs), who have limited access to screening services [1–4]. There are three
licensed prophylactic HPV vaccines against persistent infection with HPV vaccine genotypes
and high-grade cervical intraepithelial neoplasia, pre-requisites for cervical cancer develop-
ment [5]. Cervarix1 (GlaxoSmithKline Biologicals) targets HPV genotypes 16 and 18; GAR-
DASIL1 (Merck & Co. Inc.) targets HPV 16, 18, 6, 11 [6]; GARDASIL-9 (Merck & Co. Inc.)
targets an additional five oncogenic genotypes [7]. As HPV is sexually transmitted, the World
Health Organization (WHO) recommends targeting HPV vaccination to girls prior to sexual
debut (e.g. age 9–13) because it is most efficacious in those who have not been exposed to
HPV [8].
Between 2007 and 2012, several LAMICs conducted HPV demonstration projects with vac-
cines provided by the GARDASIL1 Access Program (GAP) [9], Merck & Co., the Bill &
Melinda Gates Foundation through PATH, or through other means. Demonstration projects
are small-scale pilots through which experience can be gained in delivering the vaccine to what
is often a novel target age group [10]. In 2012 Gavi, the Vaccine Alliance, commenced support
for demonstration projects and national introductions to increase access to HPV vaccine
worldwide. The majority of demonstration projects are now Gavi-funded. National pro-
grammes may also be funded by Gavi if the country has prior experience of vaccination in the
target age group and achieved over 50% vaccination coverage. By May 2016, over 80 countries
or territories had commenced national HPV vaccination and another 38 had completed or
started HPV vaccine demonstration projects [11].
Country decision-makers face several challenges when applying for support and introduc-
ing HPV vaccine including selection of delivery strategy, effective communication with com-
munities and determining how to maximise coverage [12, 13]. At the time of this study, no
comprehensive review of results and lessons learnt from demonstration projects or early scale-
up in LAMICs had been conducted. This study aimed to synthesise lessons learnt from the
HPV demonstration projects and national programmes in LAMICs implemented between
January 2007 and May 2016 to develop recommendations for HPV vaccine delivery and accel-
erate scale-up of national programmes.
Methods
This ecological study included semi-structured key informant interviews, a systematic litera-
ture review and a review of unpublished reports. Units of analysis were: 1) countries, 2) proj-
ects/programmes, and 3) delivery experiences (Table 1).
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A mapping exercise identified all low and lower-middle income countries that had com-
pleted at least six months of an HPV vaccine demonstration project or national programme by
the end of April 2016. Data from upper-middle or high-income countries were only included
if they conducted a demonstration project or utilised an innovative dosing schedule (n = 46;
Table 2) [14]. At least another 6 LAMICs were planning to start Gavi-supported demonstra-
tion projects, but did not have data in time for inclusion in this study.
Systematic literature review
Five databases (Medline, Embase, Global Health, Africa-wide Information, ADOLEC) were
searched systematically for published literature in April 2016. Search terms relating to HPV
and vaccination were combined with country terms, with no language restrictions (S1 Table).
For each country, searches were limited to publications from the first year of HPV vaccine
experience onwards, to reduce the number of articles retrieved that did not document vaccine
delivery (e.g. hypothetical acceptance studies). Reference lists of identified reviews and
retrieved papers were checked for missing papers. One author was contacted for an unpub-
lished manuscript. Titles and abstracts of 2936 references were double screened by two of
three study investigators using exclusion criteria set a-priori in a protocol as per PRISMA
guidelines [85] (Fig 1). Exclusion criteria were: 1) not focused on HPV vaccination; 2) not
focused on one of our countries of interest; 3) did not include any results from after the vac-
cine was delivered; 4) not focused on, or relevant to, the demonstration project or vaccine
introduction. Any conflicting opinions between investigators on the exclusion of abstracts
were noted and resolved after full text review by the third investigator. A total of 240 full texts
were screened by the same study personnel using the same exclusion criteria. Review articles
were identified and searched for further references but were not included in the final selection
of articles for data extraction.
Unpublished reports
Authors systematically searched two databases (Open Grey, ProQuest) and several websites
(national Ministries of Health (MOH), WHO Global Immunization News, Pan-American
Health Organization newsletters, scientific conferences on HPV) for unpublished literature
through March 2016. Unpublished data were solicited directly from country representatives
and stakeholders involved in HPV projects/programmes.
Key informant interviews
Representatives from each HPV vaccine project/programme in 44 of the 46 countries were
approached for interview in order to fill gaps in the data in the published and unpublished
Table 1. Key definitions.
Delivery
experience
The specific target population (age range in years or school grade) and vaccination
venue (health facility-based, school-based, outreach, or a combination of the three)
within a specific project/programme (defined by the funding source). E.g. A country that
was funded for 2 years for a demonstration project and implemented one year of
school-based delivery and a second year of health facility based strategy, was
classified as having contributed information from one project but two delivery
experiences.
Programme A national HPV vaccination programme.
Project The activities funded through a specific GAP, Gavi or other funder support for a
demonstration/pilot project. A distinct project was defined by the funder and/or
implementer and grant award details.
https://doi.org/10.1371/journal.pone.0177773.t001
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Table 2. Countries included in this study with publications included from the systematic literature search.
Country Income1 Primary school net
enrolment ratio2
Demo3/ National
(funding source)3
Vaccination venue(s) Year/s HPV
vaccination
Bhutan [15–21] Lower-
middle
88.1 (2013) Demo (GAP) School 2009
National (ACCF) School 2010
Health facility + outreach 2011–13
School + health facility + outreach 2014-
Bolivia [19, 20] Lower-
middle
81.6 (2013) Demo 1 (GAP) School + health facility 2009
Demo 2 (GAP) School + health facility + outreach 2009
Demo 3 (GAP) School + health facility 2010
Demo 4 (GAP) School + health facility 2010–11
Botswana [22–24] Upper-
middle
83.8 (2009) Demo (WB) School 2013
Demo (MOH) School + health facility 2014
National (Govt.) School + health facility 2015
Brazil [25–29] Lower-
middle
94.4 (2005) Demo (GAP) School 2010–11
Demo (MOH) School + outreach 2010–12
National (Govt.) School + health facility 2014-
Burkina Faso Low 67.5 (2013) Demo (Gavi) School + health facility + outreach 2015-
Cambodia [19, 20] Low 98.4 (2012) Demo 1 (GAP) Health facility 2009–10
Demo 2 (GAP) School + health facility 2010–11
Cameroon [19, 20, 30–34] Lower-
middle
91.5 (2012) Demo 1 (GAP) School + health facility 2010
Demo 2 Gavi) School + health facility + outreach 2015-
Chile [35] High 92.7 (2012) National (Govt.) School + health facility 2014-
Coˆte d’Ivoire Lower-
middle
61.9 (2009) Demo (Gavi) School + health facility + outreach 2015-
Ethiopia Low 67.9 (2006) Demo (Gavi) School + outreach 2015-
The Gambia Low 68.7 (2013) Demo (Gavi) School + health facility + outreach 2015-
Georgia [20] Lower-
middle
96.5 (2013) Demo 1 (GAP) Health facility 2010
Demo 2 (GAP) Health facility + outreach 2010–14
Ghana Lower-
middle
88.9 (2014) Demo 1 (GAP) School 2013
Demo 2 (Gavi) Year 1: School. Year 2: School + health facility + outreach 2013–15
Guyana Lower-
middle
71.5 (2012) Demo (GAP) School + health facility 2012–13
National (Govt) NA 2014
Haiti [19, 20] Low NA Demo (GAP) School 2009
Honduras [20] Lower-
middle
89.3 (2013) Demo 1 (GAP) School + health facility + outreach 2011
Demo 2 (GAP) School 2012–13
Demo 3 (GAP) School + health facility 2014
National (Govt.) School + health facility 2015-
India [36–40] Lower-
middle
93.3 (2011) Demo (PATH) School + health facility campaign 2009–10
School and health facility monthly delivery 2009–10
Kenya [20, 41, 42] Low 83.6 (2012) Demo (GAP) School 2011
Demo (Gavi) School 2013–15
Kiribati Lower-
middle
NA Demo (GAP/ ACCF) School 2011–13
Laos PDR Lower-
middle
97.3 (2013) Demo (Gavi) School + health facility + outreach 2013–15
Lesotho [19, 20] Lower-
middle
79.6 (2013) Demo 1 (GAP) School 2009
Demo 2 (GAP) School 2010–11
National School 2012-
Madagascar Low 77.1 (2003) Demo (Gavi) School + health facility 2013–15
Malawi Low 96.9 (2009) Demo (Gavi) School + health facility 2013–15
Mali Low 64.4 (2013) Demo 1 (GAP) Health facility 2012
Demo 2 (Gavi) School + health facility + outreach 2015-
Moldova [20] Lower-
middle
87.9 (2013) Demo (GAP) School 2010–11
Mongolia Lower-
middle
94.7 (2013) Demo (GAP) School + health facility + outreach 2012
School 2014
Mozambique Low 87.4 (2013) Demo (Gavi) School + health facility + outreach 2014–15
(Continued)
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Table 2. (Continued)
Country Income1 Primary school net
enrolment ratio2
Demo3/ National
(funding source)3
Vaccination venue(s) Year/s HPV
vaccination
Nepal [19, 20, 43] Low 98.5 (2013) Demo 1 (ACCF) School 2008
Demo 2 (GAP/ACCF) School + health facility 2010
Demo 3 (ACCF) School + health facility 2011–14
Demo 4 (Gavi) School + health facility 2015-
Niger Low 62.8 (2012) Demo (Gavi) School + outreach 2014–15
Papua New Guinea Lower-
middle
85.6 (2012) Demo (GAP) School + health facility 2012
Peru [37–39, 44–49] Upper-
middle
91.8 (2013) Demo (PATH) School + health facility + outreach 2007–08
2009–10
National (Govt) School 2011–12 2014-
Philippines Lower-
middle
88.2 (2009) Demo (Jhpiego) NA 2010
Rwanda [50–53] Low 93.4 (2013) National (Merck) School + health facility + outreach 2011–13
National (Gavi) School + health facility 2014-
Senegal Lower-
middle
73.4 (2014) Demo (Gavi) School + health facility + outreach 2015-
Sierra Leone Low NA Demo (Gavi) NA 2013
Solomon Islands Lower-
middle
80.7 (2007) Demo (Gavi) School + health facility + outreach 2015-
South Africa [54–61] Upper-
middle
89.6 (2005) Demo 1 (UCT) Health facility 2010
Demo 2 (KZN DoH) School 2011
Demo 3 (UoS) School 2013
National (Govt.) School 2014-
Tanzania [20, 39, 62–68] Low 83.5 (2013) Demo 1 (GAP) School—age and grade criteria tested 2010–11
2010–11
Demo 2 (Gavi) Year 1: School & health facility. Year 2: Health facility
+ outreach
2014-
2016-
Thailand [69, 70] Upper-
middle
95.6 (2009) Demo (Jhpiego) NA 2010
Togo Low 97.5 (2013) Demo (Gavi) School + health facility + outreach 2015-
Uganda [20, 37–39, 48, 71–81] Low 91.5 (2013) Demo 1 (PATH/ MOH) School + health facility 2008–09 2010–11
School + health facility + outreach 2008–09 2010–11
Demo 2 (GAP) Health facility 2010
Demo 3 (Merck) School + outreach 2012–14
Natl (Gavi) Health facility + outreach 2015-
Uzbekistan [20] Lower-
middle
88.5 (2011) Demo (GAP) Health facility 2009
National (Gavi) School + health facility 2016-
Vanuatu Lower-
middle
98.9 (2005) Demo (ACCF) School 2009
National (ACCF) School + outreach 2013-
Vietnam [37–39, 48, 72, 79, 82–
84]
Lower-
middle
98.1 (2012) Demo (PATH/ MOH) School + health facility 2008–10
Health facility 2008–10
Zambia Lower-
middle
91.4 (2013) Demo (GAP) School + health facility 2013–14
Zimbabwe Low 93.9 (2012) Demo (Gavi) School + health facility + outreach 2015-
1 World bank classifications of income group, February 2014.
2 Information sourced from UNESCO Institute of Statistics, educational attainment most recently available data; year is indicated in brackets.
Italicised text indicates experiences with incomplete data due to start date; this data was obtained in the process of data collection when countries were
questioned about future or current HPV vaccine activity; only experiences with at least one year of implementation were included in analyses.
Abbreviations: ACCF, Australian Cervical Cancer Foundation; CHW, community health worker; Demo, demonstration/pilot project; GAP, Gardasil®
Access Program; est., estimated; HPV, human papillomavirus; KZN DoH, KwaZulu-Natal Department of Health; MOH, ministry of health; national, national
programme; NA, not available; UCT, University of Cape Town; UNESCO, the United Nations Educational Scientific and Cultural Organisation; UoS,
University of Stellenbosch; WB, World Bank.
https://doi.org/10.1371/journal.pone.0177773.t002
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literature. No significant gaps were identified in two countries. After written informed consent
was obtained, interviews were conducted by phone or in-person. A topic guide was adapted to
address identified knowledge gaps. All interviewees were assured of confidentiality and ano-
nymity to encourage openness about experiences.
Data extraction
KG, NH, SK, SMJ extracted data during February-May 2016, using an Excel-based matrix of
key areas of inquiry informed by WHO’s new vaccine introduction guidelines [86]. The matrix
was piloted and revised twice, with two consistency checks conducted. Data from published,
unpublished and interview sources were extracted into the same matrix.
Data analysis
Country data from all sources were triangulated and analysed together in seven themes: prepa-
ration, communications, delivery, achievements, sustainability, integration and value of dem-
onstration projects. Data were grouped by calendar year, world region and type of funder or
implementer to analyse patterns.
Fig 1. Systematic literature review flow. 1Exclusion criteria were: 1) not focused on HPV vaccination; 2) not
focused on one of our countries of interest; 3) did not include any results from after the vaccine was delivered;
4) not focused on, or relevant to, the demonstration project or vaccine introduction. Review articles were
identified and searched for further references but were not included in data extraction.
https://doi.org/10.1371/journal.pone.0177773.g001
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Qualitative data were analysed thematically across data sources. Quantitative data (e.g. cov-
erage, adverse events) were analysed descriptively to present frequencies and proportions.
Reported coverage estimates were categorised as percentages because not all projects/pro-
grammes shared numerator and denominator data to enable coverage calculations.
The London School of Hygiene & Tropical Medicine Research Ethics Committee approved
the study in March 2015.
Results
In total, 61 published articles, 11 conference abstracts, and 188 unpublished documents were
included in the review. Unpublished documents received from country representatives and
international partners from 44 of the 46 countries included: GAP final reports (n = 16); Gavi
post-introduction evaluations (PIEs; n = 9); other PIEs (n = 2); Gavi cost analyses (n = 6); Gavi
coverage surveys (n = 9); and other internal reports (n = 146). Additionally, 56 interviews were
conducted covering experiences from 40 countries (59 demonstration projects, 11 national
programmes). Four country representatives invited to interview either refused to participate
or did not respond.
The 46 countries that implemented HPV vaccination projects/programmes between Janu-
ary 2007 and May 2016 accumulated 120 years of implementation experience (Table 2). This
included 12 national programmes and 66 demonstration projects. By May 2016, 39% of coun-
tries (n = 18) had 2–3 years of experience, 35% (n = 16) had one year of experience and 26%
(n = 12) had four or more years of experience in national programmes or multiple demonstra-
tion projects. Twenty-one projects/programmes in 19 countries had implemented a two-dose
HPV vaccine schedule by May 2016; all others implemented a three-dose schedule. HPV vacci-
nation was free-of-charge to recipients in all projects/programmes.
Preparation
Leadership and planning. Three-quarters of projects/programmes were led by the MOH,
with lead departments varying between cancer, school/sexual/reproductive health and immu-
nisation. Some early demonstration projects were led by hospitals or non-governmental orga-
nisations (NGOs) with varying degrees of national immunisation team (EPI) involvement, a
few operated without government input. Some interviewees from countries without school/
adolescent health programmes reported confusion over which department should lead coordi-
nation of HPV vaccination and leadership was decided opportunistically, based on capacity.
However, it was clear that EPI involvement was necessary to ensure smooth implementation
and reduce workload (e.g. to avoid establishment of parallel vaccine management and report-
ing systems). Delivery experiences with MOH ownership and high EPI involvement were
more likely to achieve good coverage in comparison to others run by external partners or with
low EPI involvement. Sources indicated that to be effective, microplanning needed involve-
ment of the Ministry of Education (MOE), teachers and school administrators and health
representatives.
District selection. Among the 53 projects in 40 countries with data, areas included in a
quarter of the demonstration projects represented those with routine immunisation coverage
and education performance similar to the national average (15 projects), a fifth represented
convenient districts (i.e. close to the capital city and/or had good infrastructure; 10 projects),
30% were representative of both urban and rural areas (16 projects). Projects could be classi-
fied in more than one of these categories. Some projects selected districts that included varied
or particularly challenging areas (13%, 7 projects) but 17% (5 projects) selected areas with
higher than national average EPI coverage and educational attainment.
Human papillomavirus vaccination in 45 low- and middle-income countries
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Enumeration of the population eligible for vaccination. Accurate enumeration was
challenging in most countries and affected estimations of the doses required, transport and
coverage calculations. School headcounts/ register checks used in conjunction with school
enrolment rates, were the most accurate methods to calculate the target population number,
aside from conducting a full census, which was prohibitively expensive in most countries.
However, the number of out-of-school girls was often unknown throughout projects/
programmes.
Cold-chain and waste management. The most efficient method of transporting HPV
vaccines was alongside other routine vaccines. However, in some countries this proved prob-
lematic due to the demonstration project timeline not aligning with quarterly vaccine delivery
schedules. Providing separate transport increased the cost of delivery. Routine national immu-
nization cold-chain facilities were generally used. Waste management generally followed rou-
tine practices and needed improvement in many countries.
Staff training. Cascade training (i.e. national staff training regional staff, who train dis-
trict-level, who train field-staff), was reportedly less expensive than transporting teams of
national trainers around the country. However, periodic supervision was considered necessary
in order to ensure that the quality of information transfer between levels in the cascade was
maintained.
Communications
HPV vaccination as a cancer prevention method was more frequently emphasized than its role
in sexually transmitted infection (STI) prevention, in order to avoid stigmatising the vaccine
and to reduce confusion with other STI prevention messages [87]. Messages targeted the
whole community with information focused on cervical cancer, the importance of HPV vacci-
nation, government endorsement, doses required, timing and venues, and lack of long-term
adverse effects. Problems were reported when social mobilisation occurred less than a month
before vaccination and high-level officials did not deal with rumours rapidly.
Delivery
Venue and target. Schools were the most commonly used vaccination venue, with 87%
(78/89) of delivery strategies using them, with or without additional health facility or outreach
components (Table 2). Strategies including schools gained high coverage but were reported to
be resource intensive in countries without existing school-based health programmes. There
were limited data on strategies that used health facilities as the only sites of vaccine delivery
(11 experiences, 5 with coverage data). In experiences that used schools, 52% (39/75) vacci-
nated a specific age group of girls, 31% (23/75) selected a school grade(s) and 17% (13/75)
vaccinated girls of a certain age within a specific school grade. Some MOH-led projects/ pro-
grammes made changes to the delivery strategy for a variety of reasons that illustrate the trade-
offs inherent in different strategies (Table 3).
Out-of-school girls. National primary school enrolment ratios indicate the proportion of
girls out-of-school was 5% or less in 23% of the countries with data (10/43), between 6% and
20% in 56% of countries (24/43), and over 20% in nine countries (range 23–38%)[14]. Almost
a third of experiences (27%) had no reported strategy for reaching out-of-school girls, another
third (35%) relied on them attending health facilities for vaccination and the remaining experi-
ences used outreach. Outreach was used in all nine countries with poor school enrolment and
reportedly increased coverage.
Duration of delivery per dose. Duration of delivery activities per dose ranged from 2–3
days to 1 month (data from 31 delivery experiences). Most experiences delivered each dose
Human papillomavirus vaccination in 45 low- and middle-income countries
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over the course of one week and activity was synchronized across districts (i.e. similar to a vac-
cination campaign). Two further experiences delivered each dose over 6 months at the health
facility and during routine outreach. There was no obvious relationship between the duration
of delivery activities per dose and vaccination coverage. However, countries reported that it
was useful to provide a second opportunity for girls to obtain the vaccine (e.g. ‘mop-up’ vacci-
nation days at schools) if they had initially refused or were absent. The dose schedule recom-
mendation change in April 2014 [88, 89] resulted in data on two-dose schedules from 19
countries. The delivery of two doses rather than three doses was reported as logistically easier
to fit in to the school year and cheaper by all 10 countries that had changed vaccine schedule.
One country reported an extended interval of 12 months between doses made enumeration
and delivery in a single campaign each year easier.
Catch-up. Three national programmes conducted catch-up vaccination in older age
groups either by vaccinating girls aged 9–15 or 9–18 years, or by additionally vaccinating the
second and third grades of secondary school. Two further national programmes vaccinated
9–13 year olds in a small catch-up campaign in their first year of the programme. No evalua-
tion results were available for catch-up campaigns.
Health workforce. Almost all countries used qualified nurses to deliver the vaccine; one
used community health workers (CHWs). CHWs and teachers were reportedly invaluable at
vaccination venues to ensure efficient delivery. Disruption of other health services during
HPV vaccine delivery was not homogenous within a country. Strategies to minimise the
impact of the HPV school/outreach activities on routine services included: integration into
existing outreach days, longer working days, use of staff from other areas or services and task-
shifting responsibilities to CHWs. One country delivered each dose over a month instead of
Table 3. Changes in delivery strategy.
Countries Original strategy Change in strategy Reasons for changes
Change from school-based
campaign (3 countries)
School or school +
health facility
Health facility with/ without
outreach
High level of resources required for outreach visits to schools
and concern over sustainability. One country subsequently
switched back to school based strategy, as HPV vaccine
coverage was low with health facility delivery.
Removal of out-of-school
strategy (2 countries)
School + health
facility + outreach
School + health facility or
school-only
Outreach had proven resource intensive, with logistical
difficulties and only incremental gains in coverage.
Addition of strategies to reach
out-of-school girls (5 countries)
School or Health
facility
School + health facility +/-
outreach or Health facility +
outreach
To increase coverage and equity of HPV vaccination by including
out-of-school girls.
Countries Original target
population
Change to target population Reasons for changes
Change to identification of girls
by grade (5 countries)
Age Grade Identifying eligible girls by age was difficult if exact birth date/
year was not known or documented. It was unacceptable to
separate some girls from their classmates to receive the vaccine
while other class members were not vaccinated.
Change to identification of girls
by age (4 countries)
Grade or age within
a grade
Age It is easier to explain to the community and aligns with routine
EPI, which used age cohorts. Easier to estimate the
denominator/ target population even if girls are spread in
different grades. To purposely assess a different strategy in the
second year of the project.
Adaption of age/grade criterion
to be more appropriate (5
countries)
Grade More appropriate grade A higher concentration of eligible girls were in a higher/lower
grade.
Age 10 out-of-
school
Age 9–13 out-of-school The relative ease of identifying ‘pre-pubertal’ girls around the age
of 9–13 years in the community in comparison to trying to find
exactly age 10 girls.
https://doi.org/10.1371/journal.pone.0177773.t003
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short ‘campaign-style’ delivery. Supervision was reported as necessary, but supervisor and vac-
cinator allowances and transport were frequently reported as being drivers of high delivery
costs.
Adverse events. Reported adverse events (AEs) were below 1% and minor across 56 deliv-
ery strategies in 44 countries that provided data. Monitoring, reporting and response proce-
dures were consistent with those for other vaccines, although teachers were mentioned as a
useful and, in some countries, novel resource in monitoring AEs.
Achievements: Vaccine uptake, completion and coverage
Coverage was reported by 65% of experiences (60/92); only 17 projects conducted coverage
surveys, the remainder relied on administrative coverage. Uptake, completion and final dose
coverage achievements were high, with no estimates below 50% (Table 4). Experiences that
achieved high coverage included schools as a vaccination venue, had high EPI and MOE
involvement in both planning and implementation and included a strategy to reach out-of-
school girls if school enrolment rates were variable. Other factors reported to encourage high
coverage were: political commitment, good social mobilisation, community engagement and
timely delivery of the vaccine on scheduled dates within one school year.
Integration
Projects implemented with MOH involvement generally used EPI structures and processes for
vaccine delivery. However, the small scale of projects made integration difficult to assess and
sometimes led to establishment of parallel processes for monitoring and evaluation, supervi-
sion, vaccine transport and staff remuneration, as HPV vaccine was not seen as part of the
‘routine’ workload.
Joint delivery of HPV vaccine with other interventions was limited. One programme deliv-
ered HPV vaccine alongside a hepatitis B vaccination campaign. Eight projects/programmes
attempted delivery with tetanus toxoid vaccine or deworming and vitamin A supplementation
within school health programmes; six reported coverage estimates, which were variable. Edu-
cational messages on reproductive health or hygiene issues were delivered at the same time as
HPV vaccine in eleven projects/programmes. Two externally-led projects/programmes deliv-
ered the first dose alongside a cervical cancer screening programme for mothers. No critical
evaluations of joint delivery were available.
Table 4. Coverage achievements across delivery experiences.
Characteristic Uptake (number (%))1 Completion (number (%)) Final dose coverage2 (number
(%))
90% 70–89% 50–69% Total 90% 70–89% 50–69% Total 90% 70–89% 50–69% Total
School only 9 (50) 7 (39) 2 (11) 18 13 (68) 6 (32) 0 19 8 (40) 11 (55) 1 (5) 20
Health facility (+/- outreach) 3(60) 2 (40) 0 5 1 (20) 4 (80) 0 5 2 (40) 1 (20) 2 (40) 5
School + health facility (+/- outreach) 19 (58) 14 (42) 0 33 17 (57) 13 (43) 0 30 15 (43) 13 (37) 7 (20) 35
All experiences 31 (55) 23 (41) 2 (4) 56 31 (57) 23 (43) 0 48 25 (42) 25 (42) 10 (17) 60
1 Counts of the number of experiences achieving each category of coverage are presented with row percentages, i.e. among those strategies with data,
57% of school only strategies obtained #x2265;90% uptake compared to 50% of health facility strategies obtaining90% uptake. Excludes projects/
programmes that started in 2015 or later
2 Coverage of a 2 or 3 dose regimen (only 10 experiences had coverage data on 2-dose regimen)
https://doi.org/10.1371/journal.pone.0177773.t004
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Financing and sustainability
Thirty of the 66 demonstration projects were financed by GAP, through Axios Healthcare
Development. GAP donated vaccine, but no delivery costs. Gavi funded 20 demonstration
projects and provided vaccine and some delivery costs. For the first year of implementation
Gavi provided either US$ 4.80 per girl or US$50,000 for delivery, whichever amount was larg-
est. In the second year, funding was halved to account for start-up costs. PATH, through fund-
ing from the Bill and Melinda Gates Foundation and donated vaccine from GSK and Merck,
financed four projects; 12 were supported by other means. Gavi, Merck, the Australian Cervi-
cal Cancer Foundation (ACCF) and national governments funded the national programmes.
Countries reported considerable uncertainty over the availability of future financing. The
cost of school-based delivery was of concern for many where there were not existing school-
based health programmes. In addition to the delivery strategy changes in Table 3, six countries
stated that they planned to change from a school-based strategy to a health facility-based strat-
egy in the future, due to the high level of resources required for school visits, specifically for
transport and staff per diems.
Discussion
There is now considerable experience in HPV vaccine delivery in LAMICs. School-based
delivery to this target group is no longer ‘novel’. Many lessons have been learnt that should
make planning easier for countries still considering whether to introduce HPV vaccination.
Recommendations (Table 5; S2 Table) and outputs for decision-makers are available online
[90].
Our findings are limited by the variation in data availability; some topics were rarely
reported, or the data was highly variable in quality (e.g. coverage). Representatives from four
countries did not respond or refused interviews. As we relied on data supplied by country rep-
resentatives, the availability of data may have been lower for less successful projects/pro-
grammes. Only nine of the 20 Gavi-supported projects had completed their second year
during the period of data collection.
Lessons learnt, drivers of high coverage and key mobilisation messages were consistent
across types of demonstration project and world regions, i.e. Africa (23 countries), Asia (10),
Americas (7), Oceania (4), Europe (2). Limited EPI involvement is unlikely to be an issue in
most future demonstration projects as involvement is required for Gavi applications [10]. Les-
sons were similar to key findings documented during initial demonstration projects in 2007
[38, 65]. However, the substantial challenges in estimating target population size have not
been stressed in previous publications [12, 38]. Enumeration accuracy impacted vaccine
requirement projections and coverage calculations in almost all countries included.
Most experience to date is with school-based delivery. Funders should encourage countries
to test different approaches as more data is needed on more sustainable strategies. If alternative
strategies result in unacceptable levels of coverage, LAMIC may need increased funding to
deliver school-based programmes. Limited attempts to reach out-of-school girls did not greatly
affect coverage in countries that attain over 80% net school enrolment [14]. However, not pro-
viding an opportunity for out-of-school girls to be vaccinated perpetuates inequity.
Conclusions
HPV vaccine demonstration projects and national programmes to date in LAMICs have
achieved high coverage. However, the expense of school-based delivery is of concern for the
future sustainability of HPV vaccination programmes. Demonstration projects could better
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inform national programmes if they provided lessons in challenging areas and populations or
tested more sustainable delivery strategies.
Supporting information
S1 Table. An example of the systematic search terms used and results retrieved in the data-
base: Medline (OvidSP); 4th April 2016.
(DOCX)
S2 Table. Summary of all recommendations.
(DOCX)
Table 5. Key recommendations.
Section Recommendations
Preparation Planning processes should include representatives from the ministries of health,
education and finance.
National immunisation programme involvement is critical for effective vaccine delivery
Communications Social mobilisation in communities should begin early (at least one month before
vaccination, earlier if possible).
Messages should focus on: cervical cancer prevention; safety and efficacy, including
lack of fertility impact or long-term adverse effects, government endorsement, delivery
timing and venues and the need to return for a second dose
Members of government or WHO representatives should issue responses to rumours
as quickly as possible.
Consent processes should be consistent with existing routine EPI consent policy to
avoid rumours.
Delivery In areas with variable school attendance, specific mobilisation of out-of-school girls and
an opportunity for them to receive the vaccine should be provided.
If resources allow, planning a two-stage delivery of each dose can be successful in
reaching those girls who initially refused vaccination.
Countries need to be aware that HIV infected girls require 3 doses and should develop
specific strategies to offer them the 3-dose regimen.
Vaccination teams can include teachers and CHWs in order to decrease the number of
qualified nurses needed for vaccine delivery sessions
Achievements Including a component of school-based delivery can yield high coverage, if resources
allow. If school enrolment is low, a mixture of strategies could be important in order to
attain good coverage.
More evaluation of health facility only strategies is needed.
An opportunity for girls who missed doses to receive the vaccine should be supplied,
either at return visits to schools or referral to health facility or outreach sites, depending
on the resources available.
Sustainability More research should be conducted on scale-up experiences.
Where feasible (e.g. in terms of funding and country experience with introducing
vaccines), consider phased national implementation rather than demonstration
projects
Further exploration of sustainable funding options should be conducted and
disseminated, to encourage countries to scale-up demonstration projects
Integration Rigorous evaluation of combined interventions with HPV vaccine delivery is needed to
assess the effect on implementation, coverage, workload and cost. Funding agencies
should systematically encourage this.
Gradual integration of processes into routine processes should be planned and
formalised after the first round of vaccination is completed.
Opportunities to initiate or strengthen existing school health programmes and/or pre-
adolescent/adolescent health should be seized through on-going collaboration with
partners (e.g. MOE, reproductive health departments).
https://doi.org/10.1371/journal.pone.0177773.t005
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